Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Charles River Laboratories International, Inc. (CRL : NYSE)

• Company Description    Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. Number of Employees: 20,000

• Price / Volume Information    Yesterday's Closing Price: $223.35 Daily Weekly Monthly 20 Day Moving Average: 643,780 shares Shares Outstanding: 50.81 (millions) Market Capitalization: $11,347.27 (millions) Beta: 1.27 52 Week High: $460.21 52 Week Low: $217.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.59% 2.13% 12 Week -21.48% -14.21% Year To Date -40.72% -28.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 251 BALLARDVALE STREET - WILMINGTON,MA 01887 USA ph: 781-222-6000 fax: 978-988-5665 askcharlesriver@crl.com http://www.criver.com

• General Corporate Information    Officers James C. Foster - Chairman; President and Chief Executive Officer David R. Smith - Vice President and Chief Financial Officer Nancy C. Andrews - Director Robert J. Bertolini - Director Deborah T. Kochevar - Director Peer Information Charles River Laboratories International, Inc. (CHCR) Charles River Laboratories International, Inc. (ESRX) Charles River Laboratories International, Inc. (MYDP) Charles River Laboratories International, Inc. (GBCS) Charles River Laboratories International, Inc. (LAXAF) Charles River Laboratories International, Inc. (IPCM) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Medical Services Sector: Medical CUSIP: 159864107 SIC: 8731 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/03/22 Share - Related Items Shares Outstanding: 50.81 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $11,347.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $2.83 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $11.63 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 14.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/22

• Fundamental Ratios P/E Current FY Estimate: 19.20 Trailing 12 Months: 21.17 PEG Ratio: 1.37 Price Ratios Price/Book: 4.34 Price/Cash Flow: 14.16 Price / Sales: 3.13 EPS Growth vs. Year Ago Period: 8.70% vs. Previous Quarter: 10.44% Sales Growth vs. Year Ago Period: 10.84% vs. Previous Quarter: 0.98% ROE 03/31/22 - 21.90 12/31/21 - 22.38 09/30/21 - 23.14 ROA 03/31/22 - 7.78 12/31/21 - 7.97 09/30/21 - 8.36 Current Ratio 03/31/22 - 1.34 12/31/21 - 1.23 09/30/21 - 1.40 Quick Ratio 03/31/22 - 1.12 12/31/21 - 1.04 09/30/21 - 1.22 Operating Margin 03/31/22 - 14.95 12/31/21 - 14.99 09/30/21 - 15.30 Net Margin 03/31/22 - 11.64 12/31/21 - 11.04 09/30/21 - 11.58 Pre-Tax Margin 03/31/22 - 14.47 12/31/21 - 13.58 09/30/21 - 14.29 Book Value 03/31/22 - 51.47 12/31/21 - 50.29 09/30/21 - 48.19 Inventory Turnover 03/31/22 - 11.38 12/31/21 - 11.48 09/30/21 - 11.33 Debt-to-Equity 03/31/22 - 1.02 12/31/21 - 1.05 09/30/21 - 1.19 Debt-to-Capital 03/31/22 - 51.10 12/31/21 - 51.69 09/30/21 - 54.60

Powered by Zacks Investment Research ©